Recombinant
RabMAb

Recombinant Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] - BSA and Azide free (ab209421)

Overview

  • Product name

    Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] - BSA and Azide free
    See all Alpha-synuclein primary antibodies
  • Description

    Rabbit monoclonal [MJF-R13 (8-8)] to Alpha-synuclein (phospho S129) - BSA and Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic phosphopeptide, corresponding to residues surrounding Serine 129 of Human alpha Synuclein (UniProt: P37840).

  • Positive control

    • Recombinant alpha-synuclein, expressed in BL21 bacterial cells in the presence of Human Polo-Like Kinase 2; HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein.
  • General notes

    The formulation and the concentration of this product is compatible for metal-conjugation for mass cytometry (CyTOF®).

    Alpha-synuclein was the first gene to be linked to Parkinson’s disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
    Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.

     

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab209421 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Predicted molecular weight: 14 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function

      May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
    • Tissue specificity

      Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
    • Involvement in disease

      Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
      Parkinson disease 1
      Parkinson disease 4
      Dementia Lewy body
    • Sequence similarities

      Belongs to the synuclein family.
    • Domain

      The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
    • Post-translational
      modifications

      Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
      Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
      Ubiquitinated. The predominant conjugate is the diubiquitinated form.
      Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
    • Cellular localization

      Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
    • Information by UniProt
    • Database links

    • Alternative names

      • Alpha synuclein antibody
      • Alpha-synuclein antibody
      • Alpha-synuclein, isoform NACP140 antibody
      • alphaSYN antibody
      • MGC105443 antibody
      • MGC110988 antibody
      • MGC127560 antibody
      • MGC64356 antibody
      • NACP antibody
      • Non A beta component of AD amyloid antibody
      • Non A4 component of amyloid antibody
      • Non A4 component of amyloid precursor antibody
      • Non-A beta component of AD amyloid antibody
      • Non-A-beta component of alzheimers disease amyloid , precursor of antibody
      • Non-A4 component of amyloid precursor antibody
      • Non-A4 component of amyloid, precursor of antibody
      • OTTHUMP00000218549 antibody
      • OTTHUMP00000218551 antibody
      • OTTHUMP00000218552 antibody
      • OTTHUMP00000218553 antibody
      • OTTHUMP00000218554 antibody
      • PARK 1 antibody
      • PARK 4 antibody
      • PARK1 antibody
      • PARK4 antibody
      • Parkinson disease (autosomal dominant, Lewy body) 4 antibody
      • Parkinson disease familial 1 antibody
      • SNCA antibody
      • Snca synuclein antibody
      • Snca synuclein, alpha (non A4 component of amyloid precursor) antibody
      • SYN antibody
      • Synuclein alpha antibody
      • Synuclein alpha 140 antibody
      • Synuclein, alpha (non A4 component of amyloid precursor) antibody
      • SYUA_HUMAN antibody
      see all

    References

    ab209421 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab209421.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up